Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Key Highlights
- ➤Andrew E. Singer joins Kyntra Bio’s (KYNB) Board as independent director effective October 1, 2026
- ➤Singer joins the Audit Committee following more than 25 years in biotechnology finance
- ➤Maykin Ho steps down from Kyntra Bio’s (KYNB) Board effective September 30, 2026
- ➤Singer says Kyntra Bio strengthened its financial position and sharpened pipeline focus
Expert Statements
James A. Schoeneck, Chairman of the Board of Directors of Kyntra Bio
“We are pleased to welcome Andy to the Board. His extensive experience across biotechnology finance, corporate development and public company operations will bring valuable perspective as Kyntra Bio continues to build momentum across its differentiated rare disease and oncology pipeline and execute on its strategic priorities.”
James A. Schoeneck, Chairman of the Board of Directors of Kyntra Bio
“On behalf of the Board and the management team, I also want to thank Maykin for her service and contributions to the company.”
Andrew E. Singer, Independent Director and member of the Audit Committee of Kyntra Bio
“Kyntra Bio has taken substantial steps to strengthen its financial position and sharpen its focus on its exciting pipeline. I look forward to working with the Board and management team to support the company as it advances its programs to create long-term value.”
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.
“We are pleased to welcome Andy to the Board. His extensive experience across biotechnology finance, corporate development and public company operations will bring valuable perspective as Kyntra Bio continues to build momentum across its differentiated rare disease and oncology pipeline and execute on its strategic priorities,” said James A. Schoeneck, Chairman of the Board of Directors of Kyntra Bio. “On behalf of the Board and the management team, I also want to thank Maykin for her service and contributions to the company.”
Get started
Create a free account to read the full story.